The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%,

Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.
To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link
Key Market Insights 
  • Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems
  • Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors
  • The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains
  • Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry
  • The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics
  • Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments
  • Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems; we expect the service-based revenues to grow at a CAGR of over 8%
  • In the long term, the projected opportunity for contract biomanufacturing is anticipated to be distributed across contract service providers of different sizes, scales of manufacturing and key geographical regions

For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 
Table of Contents
 
1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines                     
 
2.         EXECUTIVE SUMMARY
 
3.         INTRODUCTION
3.1        Chapter Overview
3.2.       Overview of Biopharmaceuticals
 
3.3.       Expression Systems Used for Biopharmaceutical Production
3.3.1.    Microbial Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Fungal Expression Systems
3.3.1.3. Yeast Expression Systems                   
3.3.2.    Mammalian versus Microbial Expression Systems
3.4.       Microbial Manufacturing Process
3.4.1.    Cell Banking
3.4.2.    Upstream Processing
3.4.3.    Fermentation
3.4.4.    Downstream Processing
3.5.       Overview of Contract Manufacturing
3.6.       Need for Outsourcing Microbial Biomanufacturing Operations
3.7.       Commonly Outsourced Microbial Biomanufacturing Operations
3.8.       Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing                                        Operations
3.9.       Key Considerations while Selecting a CMO Partner
3.10.     Concluding Remarks     
 
4.         MARKET LANDSCAPE
4.1.       Chapter Overview
4.2.       Microbial Contract Biomanufacturing Market: Overall Market Landscape
4.2.1.    Analysis by Year of Establishment
4.2.2.    Analysis by Company Size
4.2.3.    Analysis by Location of Headquarters
4.2.4.    Analysis by Location of Manufacturing Facility
4.2.5.    Analysis by Scale of Operation
4.2.6.    Analysis by Type of Biologic
4.2.7.    Analysis by Type of Expression System Used
4.2.8.    Analysis by Type of Fermenter
4.2.9.    Analysis by Type of Service(s) Offered
4.2.10.  Analysis by Regulatory Accreditations / Certifications
4.3.       Regional Analysis
4.3.1.    Analysis by North America
4.3.2.    Analysis by Europe
4.3.3.    Analysis by Asia Pacific
4.3.4.    Analysis by Middle East and North Africa
 
5.         COMPANY COMPETITIVENESS ANALYSIS
5.1.       Chapter Overview
5.2.       Assumptions and Key Parameters
5.3.       Methodology
5.4.       Competitiveness Analysis
5.4.1.    Competitiveness Analysis: Companies in North America
5.4.2.    Competitiveness Analysis: Companies in Europe
5.4.3.    Competitiveness Analysis: Companies in Asia Pacific    
 
6.         COMPANY PROFILES
6.1.       Chapter Overview
6.2.       Microbial Contract Biomanufacturers based in North America
6.2.1.    AGC Biologics
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Capabilities and Facilities
6.2.1.4. Recent Developments and Future Outlook
           
6.2.2.    Aldevron
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Capabilities and Facilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3.    BioVectra
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Capabilities and Facilities
6.2.3.4. Recent Developments and Future Outlook
6.2.4.    Ology Bioservices
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Capabilities and Facilities
6.2.4.4. Recent Developments and Future Outlook
6.3.       Microbial Contract Biomanufacturers Based in Europe
6.3.1.    Eurogentec
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Capabilities and Facilities
6.3.1.4. Recent Developments and Future Outlook
6.3.2.    Northway Biotechpharma
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Capabilities and Facilities
6.3.2.4. Recent Developments and Future Outlook
6.3.3.    Porton Biopharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Capabilities and Facilities
6.3.3.4. Recent Developments and Future Outlook
           
6.4.       Microbial Contract Biomanufacturers Based in Asia Pacific
6.4.1.    EirGenix
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Capabilities and Facilities
6.4.1.4. Recent Developments and Future Outlook
6.4.2.    Etinpro
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Capabilities and Facilities
6.4.2.4. Recent Developments and Future Outlook
6.4.3.    Stelis Biopharma
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments and Future Outlook
 
7.         RECENT PARTNERSHIPS
7.1.       Chapter Overview
7.2.       Partnership Models
7.3.       Microbial Contract Biomanufacturers: Recent Partnerships
7.3.1.    Analysis by Year of Partnerships
7.3.2.    Analysis by Type of Partnership Model
7.3.3.    Analysis by Scale of Operation
7.3.4.    Analysis by Type of Biologic
7.3.5.    Analysis by Focus Area
7.3.6.    Analysis by Target Therapeutic Area
7.3.7.    Analysis by Region
7.3.7.1. Country-Wise Distribution
7.3.7.2. Intercontinental and Intracontinental Agreements
7.3.8.    Most Active Players: Analysis by Number of Partnerships
7.4.       Microbial Contract Biomanufacturers: Mergers and Acquisitions
7.4.1.    Analysis by Year of Merger / Acquisition
7.4.2.    Analysis by Type of Acquisition 
7.4.3.    Regional Analysis 
7.4.3.1. Continent-wise Distribution 
7.4.3.2. Country-wise Distribution 
7.4.3.3. Intercontinental and Intracontinental Deals 
  
7.4.4.    Most Active Players: Analysis by Number of Acquisitions
7.4.5.    Analysis by Key Value Drivers  
7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers
 
8.         RECENT EXPANSIONS
8.1.       Chapter Overview
8.2.       Microbial Contract Biomanufacturers: Recent Expansions
8.2.1.    Analysis by Year of Expansion
8.2.2.    Analysis by Type of Expansion
8.2.3.    Analysis by Scale of Operation
8.2.4.    Analysis by Type of Biologic
8.3.       Geographical Analysis
8.3.1.    Continent-wise Distribution                    
 
9.         MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS
9.1.       Chapter Overview
9.2.       Technology Platforms Commonly Used for Microbial Fermentation
9.3.       Upcoming Platforms-General Technologies
 
10.        ATTRACTIVENESS COMPETITION MATRIX
10.1.     Chapter Overview
10.2.     AC Matrix: An Overview
10.2.1.  Strong Business Segment
10.2.2.  Average Business Segment
10.2.3.  Weak Business Segment
10.3.     AC Matrix: Analytical Methodology
10.4.     AC Matrix: Analyzing the Data for North America
10.5.     AC Matrix: Analyzing the Data for Europe
10.6.     AC Matrix: Analyzing the Data for Asia Pacific and Middle East
 
11.        MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1.     Chapter Overview
11.2.     Assumptions and Parameter Definitions
11.2.1.  Scenario 1
11.2.2.  Scenario 2
11.2.3.  Scenario 3
11.2.4.  Scenario 4
11.3.     Concluding Remarks
                                                                        
12.        BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING 
12.1.     Chapter Overview
12.2.     List of Microbial Biopharmaceutical Manufacturing Initiatives of Big Pharma Players
12.2.1.  Analysis by Number of Initiatives
12.2.2.  Analysis by Year of Initiative
12.2.3.  Analysis by Company and Year of Initiative
12.2.4.  Analysis by Purpose of Initiative
12.2.5.  Analysis by Company and Purpose of Initiative
12.2.6.  Analysis by Type of Initiative
12.2.7.  Analysis by Scale of Operation
12.2.8.  Analysis by Type of Drug Molecule
12.2.9.  Analysis by Type of Microbial Expression System Used              
12.2.10. Geographical Analysis by Investment Made
12.3.     Competitive Benchmarking of Big Pharmaceutical Players
12.3.1. Big Pharma Summary
 
13.        CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE                           MOLECULE DRUGS / THERAPIES
13.1.     Chapter Overview
13.2.     Small Molecule and Large Molecule Drugs / Therapies    
13.2.1. Comparison of Key Characteristics
13.2.2. Comparison of Microbial Manufacturing Process
13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules
13.2.3. Comparison of Key Manufacturing-related Challenges
                                                
14.        MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1.     Chapter Overview
14.2.     Key Assumptions and Forecast Methodology
14.3.     Overall Microbial Contract Biomanufacturing Market, 2020-2030
14.3.1.  Microbial Contract Biomanufacturing Market for APIs, 2020-2030
14.3.2.  Microbial Contract Biomanufacturing Market for FDFs, 2020-2030           
14.4.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
14.5.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used
14.6.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation
14.7.     Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of           End User
14.8.      Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions          
14.8.1.   Microbial Contract Biomanufacturing Market in North America, 2020-2030
14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins
14.8.1.2. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes
14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth   Hormones
14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody-based Drugs
14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics
14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations
14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies
14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
14.8.2.    Microbial Contract Biomanufacturing Market in Europe, 2020-2030
14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins
14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes
14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones
14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody-based Drugs
14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics
14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations
14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies
14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized    Companies
14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
14.8.3.  Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody- based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies
14.8.4.  Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030
14.8.4.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins
14.8.4.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Enzymes
14.8.4.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Growth Hormones
14.8.4.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Antibody-based Drugs
14.8.4.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Other Biologics
14.8.4.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:            Share of Bacterial Cell-based Expression Systems
14.8.4.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.4.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.4.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations
14.8.4.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations
14.8.4.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Small Companies
14.8.4.12. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Mid-sized Companies
14.8.4.13. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030:          Share of Large / Very Large Companies
14.8.5.  Microbial Contract Biomanufacturing Market in Latin America, 2020-2030
 
15.        IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET
15.1.     Chapter Overview
15.2.     Current Options and Recuperative Initiatives of Key Players
15.2.1.  KBI Biopharma
15.2.2.  Lonza
15.2.3.  Porton Pharma Solutions
15.2.4.  Wacker Biotech
15.2.5.  Wuxi AppTec
15.3.     Impact on Microbial Contract Biomanufacturing Market Opportunity
15.4.     Recuperative Strategies for CMO Businesses
15.4.1.  Strategies for Implementation in the Short / Mid Term
15.4.2.  Strategies for Implementation in the Long Term
 
16.        SWOT ANALYSIS
16.1.     Chapter Overview
16.2.     Strengths
16.3.     Weaknesses
16.4.     Opportunities
16.5.     Threats
16.6.     Comparison of SWOT Factors
 
17.        CONCLUDING REMARKS
17.1.     Chapter Overview
 
18.        INTERVIEW TRANSCRIPTS
18.1.     Chapter Overview
18.2.     Meteoric Biopharmaceuticals
18.2.1.  Company Snapshot
18.2.2.  Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer (Q4 2019)
18.3.     List Biological Laboratories
18.3.1.  Company Snapshot
18.3.2.  Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development (Q3 2019)
18.4.     OLON
18.4.1.  Company Snapshot
18.4.2.  Interview Transcript: Andrea Conforto, Sales and Marketing-Bioservices Director)
18.5.     Luina Bio
18.5.1.  Company Snapshot
18.5.2.  Interview Transcript: Max Rossetto, General Manager-Business Development
18.6.     WACKER Biotech
18.6.1.  Company Snapshot
18.6.2.  Interview Transcript: Rob van Dijk, Business Development Manager (Q4 2019)
 
19.        APPENDIX 1: TABULATED DATA
 
20.        APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

           


You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
1320 Posts

Made with by Mamby